Erratum to: Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients

Kristina Schee · Kjersti Flatmark · Ruth Holm ·
Kjetil Boye · Elisabeth Paus

Published online: 6 May 2012

© International Society of Oncology and BioMarkers (ISOBM) 2012

Erratum to: Tumor Biol. (2012) 33:73–83
DOI 10.1007/s13277-011-0247-5

The original version of this article inadvertently contained a mistake.

An incorrect version of Figure 2 was published. The correct figure appears below.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s13277-011-0247-5>.

K. Schee (✉) · K. Flatmark · K. Boye
Department of Tumor Biology, Norwegian Radium Hospital,
Oslo University Hospital,
0424 Oslo, Norway
e-mail: kristina.schee@rr-research.no

K. Flatmark
Department of Surgical Oncology, Norwegian Radium Hospital,
Oslo University Hospital,
0424 Oslo, Norway

R. Holm
Department of Pathology, Norwegian Radium Hospital,
Oslo University Hospital,
0424 Oslo, Norway

K. Boye
Department of Oncology, Norwegian Radium Hospital,
Oslo University Hospital,
0424, Oslo, Norway

E. Paus
Department of Medical Biochemistry,
Norwegian Radium Hospital, Oslo University Hospital,
0424 Oslo, Norway

E. Paus
Institute for Clinical Medicine, University of Oslo,
0424 Oslo, Norway

Fig. 2 Kaplan–Meier survival plots demonstrating the association between measured CEA and NCA-2 in bone marrow plasma and survival end points: CEA overall (a) and metastasis free (b) survival. NCA-2 overall (c) and metastasis free (d) survival